After its cannabidiol gel candidate failed a phase 3 trial in fragile X syndrome, Harmony Biosciences has now paused development of the asset in a different genetic disease. Harmony announced in ...
UCLA Health researchers have identified a potential drug target for treating Fragile X syndrome, the most common genetic ...
Blocking the brain protein EPAC2 reverses sensory hypersensitivity, social deficits, and seizures in Fragile X syndrome.
A new study shows that enhancing activity of a specific component of 'NMDA' receptors normalizes protein synthesis, neural activity and seizure susceptibility in the hippocampus of fragile X lab mice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results